MicroRNAs: Key Regulators in Lung Cancer.


Journal

MicroRNA (Shariqah, United Arab Emirates)
ISSN: 2211-5374
Titre abrégé: Microrna
Pays: United Arab Emirates
ID NLM: 101631045

Informations de publication

Date de publication:
2021
Historique:
received: 04 12 2020
revised: 11 04 2021
accepted: 14 04 2021
pubmed: 29 5 2021
medline: 14 1 2022
entrez: 28 5 2021
Statut: ppublish

Résumé

Noncoding RNAs have emerged as key regulators of the genome upon gene expression profiling and genome-wide sequencing. Among these noncoding RNAs, microRNAs are short noncoding RNAs that regulate a plethora of functions, biological processes and human diseases by targeting the messenger RNA stability through 3'UTR binding, leading to either mRNA cleavage or translation repression, depending on microRNA-mRNA complementarity degree. Additionally, strong evidence has suggested that dysregulation of miRNAs contributes to the etiology and progression of human cancers, such as lung cancer, the most common and deadliest cancer worldwide. Indeed, by acting as oncogenes or tumor suppressors, microRNAs control all aspects of lung cancer malignancy, including cell proliferation, survival, migration, invasion, angiogenesis, cancer stem cells, immune-surveillance escape, and therapy resistance; and their expressions are often associated with clinical parameters. Moreover, several deregulated microRNAs in lung cancer are carried by exosomes and microvesicles and secreted in body fluids, mainly the circulation, where they conserve their stable forms. Subsequently, seminal efforts have been focused on extracellular microRNAs levels as noninvasive diagnostic and prognostic biomarkers in lung cancer. In this review, focusing on recent literature, we summarize the deregulation, mechanisms of action, functions and highlight clinical applications of miRNAs for better management and design of future lung cancer targeted therapies.

Identifiants

pubmed: 34047262
pii: MIRNA-EPUB-115825
doi: 10.2174/2211536610666210527102522
doi:

Substances chimiques

Biomarkers, Tumor 0
MicroRNAs 0
RNA, Messenger 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-122

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Younes El Founini (Y)

Unit of Biology and Medical Research, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco.

Imane Chaoui (I)

Unit of Biology and Medical Research, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco.

Hind Dehbi (H)

Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.

Mohammed El Mzibri (M)

Unit of Biology and Medical Research, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco.

Roger Abounader (R)

Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, Virginia 22904, United States.

Fadila Guessous (F)

Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, Virginia 22904, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH